PanK Activators to Help Panthothenate Kinase-Associated Neurodegeneration (PKAN)
Official title: PanK Activators for the Treatment of Pantothenate Kinase-Associated Neurodegeneration
Funded at Virtus Therapeutics Corporation · NIH-11408936 · Data updated 2026-11-12
A new project is testing tiny molecules that could boost a key cellular helper (CoA) to slow or treat PKAN, a rare childhood neurodegenerative disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtus Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Groton, UNITED STATES) |
| Project start | September 15, 2023 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $999,841 |
| NIH project number | 2R44NS127740-03A1 |
| Project ID | NIH-11408936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents with PKAN or related PANK2 mutations who could participate in future translational studies or clinical trials.
✕Less likely to help
There may be no direct benefit for individuals without PKAN or without PANK2-related pathology.
What this research studies
PKAN is a rare, progressive brain disease caused by mutations in the PANK2 gene that leads to brain iron buildup and early disability. This project focuses on activating the human PANK3 enzyme to increase CoA levels in cells with PANK2 mutations, aiming to counter metabolic problems. Researchers are screening and optimizing chemical compounds (VTAC1–VTAC14) that strongly activate PANK3 and have shown good in vitro properties and low toxicity in several human cell types. The work includes generating data in patient-derived cells and mouse models to understand how activating PANK3 could protect brain cells. If successful, this approach could lead to a disease-modifying therapy for PKAN in affected children and potentially extend healthy years of life.
Why it matters
Potential benefit: If successful, patients with PKAN could have a new therapeutic option that preserves motor function and quality of life by improving cellular metabolism.
How similar studies have gone: Previous research shows that modulating kinase activity and CoA metabolism can impact cellular health in metabolic neurodegenerative conditions; this project builds on that concept with a disease-focused target.
Where this research is happening
-
Virtus Therapeutics Corporation
Groton, United States Active
Researchers
- Principal investigator: Regan, Jessica — Virtus Therapeutics Corporation
- Study coordinator: Regan, Jessica
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.